87
Views
50
CrossRef citations to date
0
Altmetric
Original Article

Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group

Original Article

, , , , , , , , & show all
Pages 1-9 | Published online: 11 Jun 2009

References

  • Louie K G, Ozols R F, Myers C E. Long-term results of a cisplatin-contairang combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 1986; 4: 1579–1585
  • Young R C, VonHoff D D, Gormley P. Cis-dichlorodiammineplatinum (II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 1979; 63: 1539–1544
  • Foster B J, Clagett-Carr K, Marsoni S. Role of hemamethyl-melamine in the treatment of ovarian cancer Where is the needle in the haystack. Cancer Treat Rep 1986; 70: 1003–1014
  • Levin L, Hryniuk W M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756–767
  • Vogl S E, Pagano M, Davis T E. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy. Cancer Treat Rep 1982; 66: 1285–1290
  • Fabian C J, Rasmussen S, Stephens R. Phase II evaluation of hexamethylmelamine in advanced breast cancer: A Southwest Oncology Group study. Cancer Treat Rep 1979; 63: 1359–1361
  • Vogl S E, Seltzer V, Canalog A. Laparotomy with therapeutic intent after 6 months of induction chemotherapy for bulky ovarian cancer. New Approaches in Cancer Therapy, H Cortes Funes, M. Rozencweig. Raven Press, New York 1982; 117–125
  • Oken M M, Creech R H, Tormey D C. Toxicity and response criteria of the Eastern Cooperative Oncology Group. J Clin Oncol 1982; 5: 649–655
  • Mehta C R, Patel N R. A network algorithm for performing Fisher's exact test in rxc contingency tables. J Am Stat Assoc 1983; 78: 427–434
  • Cox D R. Analysis of Binary Data. Chapman and Hall, London 1970
  • Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
  • Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
  • Cox D R. Regression models and life tables. J Royal Stat Soc (Series B) 1972; 34: 187–220
  • Mehta C R, Patel N R, Tsiatis A A: Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 1984; 40: 819–825
  • Barker G H, Wiltshaw E: Use of high-dose cir-dichlorodiamine platinum (II) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Med 1981; 88: 1192–1199
  • Bruckner H W, Wallaeh R. High-dose cisplatinum for the treatment of refractory ovarian cancer. Gynecol Oncol 1984; 12: 64–67
  • Ozols R F, Ostchega Y, Myers C E. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 1246–1250
  • Sutton G P, Stehman F B, Einhorn L H. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989; 7: 223–229
  • Hainsworth J D, Grosh W W, Burnett L S. Advanced ovarian cancer: Long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 1988; 108: 165–170
  • Piver M S, Lele S B, Marchetti D L. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988; 6: 983–989
  • Omura G A, Bundy B N, Berek J S. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Study Group study. J Clin Oncol 1989; 7: 457–465
  • Fuks Z, Rizel S, Biran S. Chemotherapeutic and surgical induction of pathologial complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage HI ovarian carcinoma. J Clin Oncol 1988; 6: 509–516
  • Van Houwelingen J C, Ten BokkelHuinink W W, Van derBurg M EL. Predictability of the survival of patients with advanced cancer. J Clin Oncol 1989; 7: 769–773
  • Vogl S E, Greenwald E, Kaplan B H. Ovarian cancer. Effective treatment after alkylating-agent failure. J Am Med Assoc 1908–1911; 241, 1979

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.